{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:42:25Z","timestamp":1794512545137,"version":"4.9.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chromosome 17p deletion (del[17p]) is associated with poor prognosis in patients with chronic lymphocytic leukemia (CLL). Venetoclax is approved for treatment of previously untreated and relapsed\/refractory (R\/R) CLL, including patients with del(17p), based on the open-label, multicenter, phase 2 M13-982 trial (NCT01889186). Here, we detail the 6-year follow-up analysis for M13-982. A total of 158 patients with previously untreated (n\u00a0= 5) or R\/R (n\u00a0= 153) del(17p) CLL received 400\u00a0mg venetoclax daily after initial ramp-up until progressive disease. After a median follow-up of 70\u00a0months, the best objective response rate (ORR) was 77% (21% complete remission [CR] and 49% partial remission [PR]), with a median duration of response (DOR) of 39.3\u00a0months (95% confidence interval [CI], 31.1-50.5). The median progression-free survival (PFS) was 28.2\u00a0months (95%\u00a0CI, 23.4-37.6), and median overall survival (OS) was 62.5\u00a0months (95%\u00a0CI, 51.7-not reached), with 16% of patients remaining on treatment after 6 years. Multivariable analysis did not identify statistically significant correlation between patient subgroups defined by clinical or laboratory variables and ORR or PFS. The most common grade \u22653 adverse events were neutropenia (42%), infections (33%), anemia (16%), and thrombocytopenia (16%). Post hoc comparative analyses of PFS and OS from treatment initiation, from a 24-month landmark, and by minimal residual disease status were performed between patients with del(17p) in the M13-982 and MURANO studies in the interest of understanding these data in another context. These long-term data show the continued benefits of venetoclax in patients with del(17p) CLL. The trial was registered at www.clinicaltrials.gov as #NCT01889186.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011741","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T16:31:42Z","timestamp":1706632302000},"page":"1992-2004","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"8","author":[{"given":"Stephan","family":"Stilgenbauer","sequence":"first","affiliation":[{"name":"1Division of CLL, Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Tausch","sequence":"additional","affiliation":[{"name":"1Division of CLL, Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"2Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Eichhorst","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[{"name":"5Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schneider","sequence":"additional","affiliation":[{"name":"1Division of CLL, Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[{"name":"6Medical Clinic I, Department of Hematology, University Hospital, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-761X","authenticated-orcid":false,"given":"Sebastian","family":"B\u00f6ttcher","sequence":"additional","affiliation":[{"name":"7Division of Internal Medicine, Medical Clinic III-Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Jiang","sequence":"additional","affiliation":[{"name":"9Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Boyer","sequence":"additional","affiliation":[{"name":"9Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Relja","family":"Popovic","sequence":"additional","affiliation":[{"name":"10AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd T.","family":"Ghanim","sequence":"additional","affiliation":[{"name":"10AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-0015","authenticated-orcid":false,"given":"Michael","family":"Moran","sequence":"additional","affiliation":[{"name":"10AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy J.","family":"Sinai","sequence":"additional","affiliation":[{"name":"10AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"10AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabanita","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"10AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Chyla","sequence":"additional","affiliation":[{"name":"10AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"11Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"2Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"issue":"Suppl","key":"2024042313310100200_bib1","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.clml.2016.02.013","article-title":"Treatment of chronic lymphocytic leukemia with del(17p)\/TP53 mutation: allogeneic hematopoietic stem cell transplantation or BCR-signaling inhibitors?","volume":"16","author":"Montserrat","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2024042313310100200_bib2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"issue":"26","key":"2024042313310100200_bib3","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2024042313310100200_bib4","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3324\/haematol.2021.280376","article-title":"A\u00a0clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib","volume":"107","author":"Mato","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2024042313310100200_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hemonc.2017.04.002","article-title":"Treatment of Del17p and\/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies","volume":"11","author":"Rafei","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"6","key":"2024042313310100200_bib6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00277-019-03679-x","article-title":"Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience","volume":"98","author":"Helbig","year":"2019","journal-title":"Ann Hematol"},{"issue":"17","key":"2024042313310100200_bib7","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2020002184","article-title":"Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2024042313310100200_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"25","key":"2024042313310100200_bib9","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2024042313310100200_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024042313310100200_bib11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024042313310100200_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024042313310100200_bib13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2024042313310100200_bib14","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patientswith chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"2024042313310100200_bib15","volume-title":"Venclexta\u00ae (venetoclax) [package insert]","year":"2022"},{"key":"2024042313310100200_bib16","author":"Venclyxto","year":"2022"},{"issue":"12","key":"2024042313310100200_bib17","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2024042313310100200_bib18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2024042313310100200_bib19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"issue":"21","key":"2024042313310100200_bib20","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2024042313310100200_bib21","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1002\/ajh.26411","article-title":"Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy","volume":"97","author":"Popovic","year":"2022","journal-title":"Am J Hematol"},{"key":"2024042313310100200_bib22","unstructured":"Venetoclax. Package insert. AbbVie Inc; 2020. Accessed 29 April 2022. https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf."},{"issue":"1","key":"2024042313310100200_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/hematology.2020000160","article-title":"Treatment of relapsed chronic lymphocytic leukemia after venetoclax","volume":"2020","author":"Thompson","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2024042313310100200_bib24","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1097\/HS9.0000000000000752","article-title":"Successful retreatment with venetoclax in a patient with chronic lymphocytic leukemia","volume":"6","author":"Jackson","year":"2022","journal-title":"Hemasphere"},{"issue":"10","key":"2024042313310100200_bib25","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.2020009578","article-title":"Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy","volume":"138","author":"Ma","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2024042313310100200_bib26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"34","key":"2024042313310100200_bib27","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024042313310100200_bib28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jha2.177","article-title":"Addition of rituximab in relapsed\/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy","volume":"2","author":"Handunnetti","year":"2021","journal-title":"EJHaem"},{"issue":"4","key":"2024042313310100200_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024042313310100200_bib30","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024042313310100200_bib31","unstructured":"Ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukaemia (CLL) (CLL17). ClinicalTrials.gov identifier: NCT04608318. Accessed 23 April 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04608318."},{"issue":"Suppl 2","key":"2024042313310100200_bib32","first-page":"S11","article-title":"Management of relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Woyach","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1992\/2222876\/blooda_adv-2023-011741-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1992\/2222876\/blooda_adv-2023-011741-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T09:31:22Z","timestamp":1713864682000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/1992\/514763\/Six-year-follow-up-and-subgroup-analyses-of-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011741","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}